Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

C3118

Sigma-Aldrich

CPNQ

≥98% (HPLC), solid

Sinonimo/i:

5-[4-(4-chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline, B2

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

5 MG
156,00 €

156,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Scegli un formato

Cambia visualizzazione
5 MG
156,00 €

About This Item

Formula empirica (notazione di Hill):
C20H17ClN4O3
Numero CAS:
Peso molecolare:
396.83
Numero MDL:
Codice UNSPSC:
12352202
ID PubChem:
NACRES:
NA.77

156,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Saggio

≥98% (HPLC)

Stato

solid

Colore

brown

Solubilità

H2O: insoluble <2 mg/mL
DMSO: >5 mg/mL

Temperatura di conservazione

2-8°C

Stringa SMILE

[O-][N+](=O)c1ccc(N2CCN(CC2)C(=O)c3ccc(Cl)cc3)c4cccnc14

InChI

1S/C20H17ClN4O3/c21-15-5-3-14(4-6-15)20(26)24-12-10-23(11-13-24)17-7-8-18(25(27)28)19-16(17)2-1-9-22-19/h1-9H,10-13H2
KLNPVNZJCWIQSK-UHFFFAOYSA-N

Azioni biochim/fisiol

CPNQ is a promoter of polyQ and α-synuclein inclusion formation and rescuer of Htt proteosomal dysfunction and α-synuclein toxicity.
Misfolded proteins accumulate in many neurodegenerative diseases, including huntingtin in Huntington′s disease and alpha-synuclein in Parkinson′s disease. The disease-causing proteins can take various conformations and are prone to aggregate and form larger cytoplasmic or nuclear inclusions. CPNQ (B2) was identified as a compound that promotes inclusion formation in cellular models of both Huntington′s disease and Parkinson′s disease. Despite the aggregate-forming specifics the compound prevents huntingtin-mediated proteasome dysfunction and reduces alpha-synuclein-mediated toxicity. These results demonstrate that compounds that increase inclusion formation may actually lessen cellular pathology in both Huntington′s and Parkinson′s diseases, suggesting a therapeutic approach for neurodegenerative diseases caused by protein misfolding. The ability of B2 to prevent toxicity, despite increasing inclusions, suggests that inclusions are beneficial rather than toxic, which will be further explored as the molecular target and mechanism. CPNQ (B2) is a desirable tool for both Huntington′s and Parkinson′s research.

Altre note

Product is air sensitive.

Pittogrammi

Skull and crossbones

Avvertenze

Danger

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organi bersaglio

Respiratory system

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Xiaofen Liu et al.
The Journal of infection, 82(2), 207-215 (2021-01-17)
Polymyxin B is a last-line antibiotic for multidrug-resistant gram-negative bacterial infections. However, limited safety and pharmacokinetic information is available. We investigated the safety and pharmacokinetics of intravenous polymyxin B in healthy subjects. An open-label, single-dose clinical trial was conducted in
Muralidhar Tata et al.
PloS one, 11(1), e0147811-e0147811 (2016-01-29)
The opportunistic human pathogen Pseudomonas aeruginosa can thrive under microaerophilic to anaerobic conditions in the lungs of cystic fibrosis patients. RNASeq based comparative RNA profiling of the clinical isolate PA14 cultured in synthetic cystic fibrosis medium was performed after planktonic
Edin Husić et al.
Bioinformatics (Oxford, England), 35(5), 769-777 (2018-08-14)
Discovering the evolution of a tumor may help identify driver mutations and provide a more comprehensive view on the history of the tumor. Recent studies have tackled this problem using multiple samples sequenced from a tumor, and due to clinical
John Karijolich et al.
PLoS pathogens, 11(11), e1005260-e1005260 (2015-11-20)
Short interspersed nuclear elements (SINEs) are highly abundant, RNA polymerase III-transcribed noncoding retrotransposons that are silenced in somatic cells but activated during certain stresses including viral infection. How these induced SINE RNAs impact the host-pathogen interaction is unknown. Here we
John K Diep et al.
International journal of antimicrobial agents, 52(3), 365-371 (2018-05-29)
A number of companies manufacture polymyxin B using United States Pharmacopeia (USP) metrics, rather than chemical composition, to report biological activity. Given that polymyxin B contains several different components, it is unknown whether pharmacokinetic and pharmacodynamic variability exists between the

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.